Structural abnormalities of chromosome 7q in chronic lymphoproliferative disorders

doi:10.1016/S0165-4608(96)00025-8

Cancer Genetics and Cytogenetics

Volume 92, Issue 1, November 1996, Pages 24-27

https://doi.org/10.1016/S0165-4608(96)00025-8 Get rights and content

Abstract

Structural abnormalities of 7q are common in myeloid malignancies but rarely reported in chronic lymphoproliferative disorders. 7q abnormalities were found in 29 of 796 patients (3.6%) with chronic lymphoid malignancies. The most common association was found in splenic lymphoma with villous lymphocytes (SLVL) in which 8 of 31 cases (26%) has one or more abnormalities of 7q. The most common abnormalities were deletions involving 7q32 and deletions or translocation of 7q22. There was no correlation between the type of lymphoid disorder or clinical course and specific structural abnormalities. We postulate that genes important in the pathogenesis of SLVL may reside on 7q22 and/or 7q32.

References (14)

S. Luna-Fineman et al.
Childhood monosomy 7: Epidemiology, biology, and mechanistic implications
Blood
(1995)
N.B. Atkin et al.
Chromosome 7q deletions: Observations on 13 malignant tumors
Cancer Genet Cytogenet
(1993)
U. Haglund et al.
Hairy cell leukemia is characterized by clonal chromosome abnormalities clustered to specific regions
Blood
(1994)
P.G. Isaacson et al.
The histopathology of splenic lymphoma with villous lymphocytes
Blood
(1994)
H.C. Kluin-Nelemans et al.
Proliferation and cytogenetic analysis of hairy cell leukemia upon stimulation via the CD40 antigen
Blood
(1994)
K. Offit et al.
Del(7)(q32) is associated with a subset of small lymphocytic lymphoma with plasmacytoid features
Blood
(1995)
F. Solé et al.
A new chromosomal anomaly associated with mature B-cell chronic lymphoproliferative disorders: del(7)(q32)
Cancer Genet Cytogenet
(1993)

There are more references available in the full text version of this article.

Cited by (38)

Role of interferon regulatory factor 5 (IRF5) in tumor progression: Prognostic and therapeutic potential
2024, Biochimica et Biophysica Acta - Reviews on Cancer
Canonically, the transcription factor interferon regulatory factor 5 (IRF5) is a key mediator of innate and adaptive immunity downstream of pathogen recognition receptors such as Toll-like receptors (TLRs). Hence, dysregulation of IRF5 function has been widely implicated in inflammatory and autoimmune diseases. Over the last few decades, dysregulation of IRF5 expression has been also reported in hematologic malignancies and solid cancers that support a role for IRF5 in malignant transformation, tumor immune regulation, clinical prognosis, and treatment response. This review will provide an in-depth overview of the current literature regarding the mechanisms by which IRF5 functions as either a tumor suppressor or oncogene, its role in metastasis, regulation of the tumor-immune microenvironment, utility as a prognostic indicator of disease, and new developments in IRF5 therapeutics that may be used to remodel tumor immunity.
Translocation t(2;7)(p11;q21) associated with the CDK6/IGK rearrangement is a rare but recurrent abnormality in B-cell lymphoproliferative malignancies
2014, Cancer Genetics
Structural abnormalities of chromosome 7q have been regularly reported in chronic B-cell lymphoproliferative disorders. They include chromosomal translocations involving 7q21, leading to overexpression of the CDK6 gene. Three different translocations, t(7;14)(q21;q32), t(7;22)(q21;q11), and t(2;7)(p11;q21), leading to the juxtaposition of the CDK6 gene with a immunoglobulin gene enhancer during B-cell differentiation, have been described. In the past 2 years, we identified three patients with lymphoproliferative malignancy associated with a t(2;7)(p11;q21). Fluorescent in situ hybridization using an IGK probe and a library of bacterial artificial chromosome (BAC) clones located in bands 7q21.2 and 7q21.3, containing CDK6, revealed that the telomeric part of the IGK probe was translocated on the der(7) within a 51-kb region upstream of the transcriptional start site of CDK6. A total of 23 patients with indolent B-cell lymphoproliferative disorders and juxtaposition of the IG and CDK6 genes, including 20 with IGK and CDK6 juxtaposition, have been reported thus far. This rearrangement leads to the overexpression of CDK6, which encodes a cyclin-dependent protein kinase involved in cell cycle G1 phase progression and G1/S transition.
Sequencing of t(2;7) translocations reveals a consistent breakpoint linking CDK6 to the IGK locus in indolent B-cell neoplasia
2013, Journal of Molecular Diagnostics
The translocation t(2;7)(p11;q21) has repeatedly been documented in association with indolent B-cell lymphoproliferative disorders (BLPDs). However, the chromosomal breakpoints associated with this recurrent translocation have rarely been characterized. Using an approach based on long-range PCR, we mapped the t(2;7) breakpoints in five patients presenting with indolent B-cell neoplasia. The sequencing of these rearrangements revealed several striking parallels across the t(2;7) breakpoints. The junction sites on 2p11 consistently mapped to the heptamer recombination signal sequence (RSS) of an immunoglobulin kappa variable gene (IGK) within the Vκ3 family, while the breakpoints on 7q21 each localized to within 4 bp of an RSS-like element located approximately 0.5 kb upstream of the transcription start site of the cyclin-dependent kinase 6 gene (CDK6). These findings confirm the significant genetic overlap arising in BLPD-associated t(2;7) translocations, and implicate the deregulated expression of CDK6 as a common molecular mechanism involved in the emergence of clonal B-cell proliferations presenting with this recurrent abnormality. In addition, the successful mapping of the t(2;7) translocations in each of five patients using a simple PCR-based protocol highlights the potential diagnostic utility of this approach during characterization of cases harboring analogous rearrangements.
Molecular characterization of a t(2;7) translocation linking CDK6 to the IGK locus in CD5<sup>-</sup> monoclonal B-cell lymphocytosis
2011, Cancer Genetics
The term monoclonal B-cell lymphocytosis (MBL) is used to characterize individuals with a circulating population of clonal B-cells and no other features of a lymphoproliferative disorder. Although several recent studies have examined the molecular basis of this condition, the subgroup of MBL lacking CD5 expression has been largely overlooked. In this study, we sequenced a t(2;7) in a patient with persistent but non-progressing CD5⁻ MBL. This revealed a breakpoint at 2p11.2 localized to the recombination signal sequence (RSS) of the immunoglobulin κ (IGK) variable gene IGKV3-15, and a breakpoint at 7q21.2 located 520 base pairs (bp) upstream of the transcription start site of cyclin-dependent kinase 6 (CDK6 ). The 7q breakpoint showed perfect sequence homology to the immunoglobulin RSS heptamer, and was located within 3 bp of a t(2;7) junction previously characterized in splenic marginal zone lymphoma (SMZL). These findings highlight a genetic link between CD5⁻ MBL and SMZL, and implicate the dysregulation of CDK6 in the emergence of this preclinical disorder.
Marginal zone lymphoma
2011, Seminars in Diagnostic Pathology
Citation Excerpt :
Until recently, no characteristic genetic alterations had been described for this entity, rendering the diagnosis of SMZL difficult in some cases. The analysis of chromosome region 7q22-36 with loss of heterozygosity and karyotyping demonstrating allelic loss in 40% of cases, a frequency higher than that observed in other B-cell neoplasms (8%).21-26 The most frequently deleted microsatellite was D7S487.
The term marginal zone lymphoma includes a collection of different diseases with some shared morphologic and pathogenic features, but distinctive clinical presentation, immunophenotype, molecular abnormalities, and treatment recommendations. This review describes the main features of splenic marginal zone lymphoma, nodal marginal zone lymphoma, and extranodal marginal zone lymphoma, mucosa-associated lymphoid tissue type.
Detailed characterization of 7q deletions by multicolor banding (mBAND) in marginal zone cell lymphoma
2007, Cancer Genetics and Cytogenetics
Citation Excerpt :
The reported incidence of deletions involving the long arm of chromosome 7 [del(7q)] in marginal zone cell lymphoma (MZL) varies from 26 to 40% in studies using cytogenetic analysis [1,2] and from 40 to 79% using a panel of microsatellite markers [3,4].
High-resolution multicolor banding (mBAND) analysis was applied to precisely fine-map the genomic extent of 7q deletions in a series of 26 marginal zone lymphoma patients displaying the abnormality on conventional karyotypes. Using this approach, the breakpoints and the extent of deletions revealed by conventional banding techniques had to be re-defined in 70% of cases. Although no common minimal region of deletion was delineated, mBAND demonstrated the involvement of the 7q32 region in more than 90% of cases. In addition, unsuspected translocations and intrachromosomal changes could be identified in four cases. Taken together, these data demonstrate that mBAND represents an alternative cytogenetic tool in the comprehensive analysis of chromosome aberrations in hematologic malignancies, allowing rapid screening and precise delineation of structural rearrangements of a defined chromosome. This also confirms the localization in the vicinity of band 7q32 of putative candidate gene(s) involved in the pathogenic development of the disease.

View all citing articles on Scopus

View full text

Original articleStructural abnormalities of chromosome 7q in chronic lymphoproliferative disorders

Abstract

Blood

Cancer Genet Cytogenet

Blood

Blood

Blood

Blood

Cancer Genet Cytogenet

Original article
Structural abnormalities of chromosome 7q in chronic lymphoproliferative disorders